×

1. Experience with a controlled-release oral morphine for cancer pain management. BS Kim, HC Chung: Postgrad Med J 67:S82, 1991
2. Overexpression of erbB-2 protein in gastric adenocarcinoma ―A Potential Role in Therapeutic Response to Adjuvant 5-FU-Doxorubicin Regimen Jae Kyung Roh, Soon Myung Paik, Hyun Cheol Chung, Woo Ik Yang, Ho Kuen Kim, In Joon Choi, Eun Hee Koh, Kyung Sik Lee, Jin Sik Min, Jeong Ku Yoon, Byung Soo Kim: Jpn J of Cancer and Chemother 19:1207-1219, 1992
3. Phase II trial for combined external radiotherapy and hyperthermia for unresectrable hepatoma. Byung Soo Kim, Hyun Cheol Chung, Jin Sil Seong, Chang Ok Suh, Gwi Eon Kim Cancer Chemotherapy Pharmacology 31 s119-127, 1992
4. Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study. JH Choi, HC Chung, NC Yoo, HR Lee, KH Lee, W Choi, HY Lim, EH Koh, JK Roh, SK Kim, WY Lee, BS Kim. Lung Cancer 10:287-296, 1994
5. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. F Czubayko, RV Smith, HC Chung, A Wellstein. J Biol Chem 154-159, 1994
6. Perioperative blood transfusions and prognosis in patients with curatively resected locvally advanced gastric cancer. JH Choi, HC Chung, NC Yoo, HR Lee, KH Lee, JK Roh, JS Min, KS Lee, BS Kim, HY Lim. Oncology 52:170-175, 1995
7. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Kyong Sik Lee, Sun Young Rha, Sea Joong Kim, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim, Hyun Cheol Chung. Clin Exp Metastasis 14:512-519, 1996
8. Overexpression of c-erbB-2 protein in gastric cancer by immunohistochemical stain. Hye Ran Lee, Hyo Dong Uhm, Joong Bae Ahn, Sun Young Rha, Jae Yong Cho, Jong In Lee, Kyong Hee Lee, Hyun Cheol Chung, Jae Kyong Roh, Jin Sik Min, Kyong Sik Lee, Dong Hwan Shin, Byung Soo Kim, Soon Won Hong, Jin Hyuk Choi. Oncology 53:192-197, 1996
9. Gastric cancer in young patients who underwent curative resection. Comparative studies with older patients. JH Choi, HC Chung, NC Yoo, HR Lee, KH Lee, JK Roh, CS Park, JS Min, KS Lee, BS Kim, HY Lim. Am J Clin Oncol 19:45-48, 1996
10. Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma. JY Cho, YH Lee, KY Chung, SK Kim, SJ Gong, NC Yoo, HC Chung, JK Roh, BS Kim. Cancer 79:462-467, 1997
11. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Joon Oh Park, Sun Young Rha, Jae Yong Cho, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung. Am J Clin Oncol. 20:569-572, 1997
12. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. Park Joon Oh, Chung Hyun Cheol, Cho Jae Yong, Rha Sun Young, You Nae Choon, Noh Sung Hoon, Kim Chong Bae, Min Jin Sik, Kim Byung Soo. Am J Clin Oncol. 20:484-489, 1997
13. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Sun Young Rha, Jae Kyung Roh, Kyong Sik Lee, Jin Sik Min, Byoung Soo Kim, Hyun Cheon Chung. Breast Cancer Res Treat 43:175-181, 1997
14. P-glycoprotein: an intermediate and point of drug response to induction chemotherapy in locally advanced breast cancer. Hyun Cheol Chung, Sun Young Rha, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, Kyi Beom Lee. Breast Cancer Res Treat 42:65-72, 1997
15. Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. Sun Young Rha, Sung Hoon Noh, Hyun Joo Kwak, Anton Wellstein, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung. Cancer Letters. 118:37-46, 1997
16. Relationship between p53 overexpression and gastric cancer progression. Hyo Dong Uhm, Soo Jung Gong, Dong Hwan Shin, Jin Hyuk Choi, Hye Ran Lee, Sung Hoon Noh, Byung Soo Kim, Jae Yong Cho, Sun Young Rha, Nae Choon Yoo, Hyun Cheol Chung, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim. Oncology 54: 166-170, 1997
17. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Sun Young Rha, Woo Ick Yang, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, and Hyun Cheol Chung. Oncology Reports 5:875-879, 1998
18. Telomerase activity and telomere length in various cell lines: Changes of telomerase activity can be another method for chemosensitivity evaluation. Kyu Hyun Park, Sun Young Rha, Chang Han Kim, Tae Soo Kim, Nae Choon Yoo, Jae Kyung Roh, Sung Hoon Noh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, Hyun Cheol Chung. International J Oncology 13:489-495, 1998
19. Alpha-fetoprotein-producing gastric cancer. Ruth Lee, Sun Young Rha, Joong Bae Ahn, Kwang Yong Shim, Jin Hyuk Choi, Ho Young Lim, Nae Choon Yoo, Sung Hoon Noh, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung. Oncol Rep 5:1179-1184, 1998
20. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Chung HC, Rha SY, Park JO, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS, Kim JJ. Breast Cancer Res Treat 49:41-50, 1998
21. Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast. Chung HC, Rha SY, Ahn JB, Shim KW, Yoo NC, Roh JK, Lee KS, Min JS, Kim BS, Kim JJ. Int J Mol Med 2:465-470, 1998
22. Effects of Interleukin-2 transduction into the human hepatoma cell lines using retroviral vector. Gong SJ, Yoo NC, Lee H, Shin DH, Uhm HD, Jeong SJ, Cho JY, Rha SY, Kim YS, Chung HC, Roh JK, Min JS, Kim BS. Oncol Rep 6:49-54, 1999
23. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Sun Young Rha, Hyun Cheol Chung, Soo Jung Gong, Kwang Yong Shim, Joong bae Ahn, Woo Ick Yang, Kyu Ho Shin, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Chong In Lee, Byung Soo Kim. Oncol Rep 6:631-637, 1999
24. Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer. Rha SY, Noh SH, Kim TS, Yoo NC, Roh JK, Min JS, Kim BS, Kim MY, Chung HC. Int J Mol Med 4:203-212, 1999
25. Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast. Rha SY, KH Pak, Kim TS, Yoo NC, Yang WI, Roh JK, Min JS, Lee KS, Kim BS, Choi JH, Lim HY, Chung HC. Int J Oncol 15:839-845, 1999
26. Correlation of tissue and blood plasminogen activation system in breast cancer. Rha SY, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS, Chung HC. Cancer Letter 150:137-145, 2000
27. Tissue urokinase-type plasminogen activator receptor levels in breast cancer. Gong SJ, Rha SY, Chung HC, Yoo NC, Roh JK, Yang WI, Lee KS, Min JS, Kim BS, Chung HC. Int J Mol Med 6:301-305, 2000
28. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. HC Jeung, SY Rha, SH Noh, JS Min, BS Kim, HC Chung. Cancer 91:2016-2025, 2001
29. Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Ahn JB, Shim KY, Jeung HC, Rha SY, Yoo NC, Kim NK, Roh JK, Min JS, Kim BS, Chung HC. Cancer Letters 167: 215-224, 2001 (
30. Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials. NK Kim, JS Min, JK Park, SH Yun, JS Sung, HC Chung, JK Roh. Jpn J Clin Oncol 31:25-29, 2001
31. Early postoperative interperitoneal chemotherapy with mictomycinC, 5-fluorouracil and cisplatin for advanced gastric cancer. Sung Hoon Noh, Chang Hak Yoo, Hyun Cheol Chung, jae Kyung Roh, Dong Woo Shin, Jin Sik Min. Oncology 60:24-30, 2001
32. The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. GE Kim, WI Yang, SW Lee, YB Kim, CO Suh, JH Yoon, TY Oh, HC Chung, BS Kim. Cancer 91:2343-2352, 2001
33. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. HC Jeung, SY Rha, WI Jang, SH Noh, HC Chung. Br J Surg 89:460-466, 2002
34. Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. Rha SY, Jeung HC, Roh JK, Kim JJ, Noh SH, Min JS, Kim BS, Chung HC. Int J Mol Med. 10:251-256, 2002
35. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, Chung HC, Kwon HJ. Jpn J Cancer Res. 93:1378-1385, 2002.
36. Expression of autotoxin (NPP-2) is closely linked to invasiveness of breast cancer cells. SY Yang, JS Lee, CG Park, SH Kim, SY Hong, HC Chung, SK Min, WH Jeung, HW Lee, HY Lee. Clin Exp Metastasis 19:603-608, 2002 (
37 An integrated proteome database for two-dimentional electrophoresis data analysis and laboratory information management system. SY Cho, KS Park, JE Shim, MS Kwon, KH Joo, WS Lee, J Chang, H Kim, HC Chung, HO Kim, YK Paik. Proteomics 2:1104-1113, 2002
38 Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Yang SH, Kim JS, Oh TJ, Kim MS, Lee SW, Woo SK, Cho HS, Choi YH, Kim YH, Rha SY, Chung HC, An SW. Int J Oncol. 22:741-750, 2003
39 Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer. Sohn JH, Jeung HC, Shin HJ, Rha SY, Roh JK, Noh SH, Min JS, Kim BS, Jang WI, Chung HC. Am J Clin Oncol. 26:203-209, 2003
40. Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer. Schneider BG, Rha SY, Chung HC, Bravo JC, Mera R, Torres JC, Plaisance KT Jr, Schlegel R, McBride CM, Reveles XT, Leach RJ. J Clin Pathol 56:141-149, 2003
41. Coordination modes vs antitumor activity: synthesis and antitumor activity of novel platinum (II) complexes of N-substituted amino dicarboxylic acids. YS Kim, R Song, HC Chung, MJ Jun, YS Sohn. J Inorg Biochem 98:98-104, 2004
42. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. GE Kim, YB Kim, NH Cho, HC Chung, HR Pyo, JD Lee, TK Park, WS Koom, M Chun, CO Suh. Clin Cancer Res 10:1366-1374, 2004
43. The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. MY Seo, SY Rha, SH Yang, SC Kim, GY Lee, CH Park, WI Yang, JB Ahn, BW Park, HC Chung. Int J Mol Med 13:17-24, 2004
44. Fabrication of high quality cDNA Microarray using a small amount of cDNA. CH Park. HJ Jeong, JJ Jung, GY Lee, SC Kim, TS Kim, SH Yang, HC Chung, SY Rha. Int J Mol Med 13:675-679, 2004
45. Lack of correlation between P-glycoprotein and chemotherapy resistance in Nasal NK/T-cell lymphomas. GE Kim, WI Yang, SW Lee, SY Rha, HC Chung, JH Cho, CO Suh, NC Yoo, JK Roh, JS Hahn. Leuk Lymphoma 45:1857-1864, 2004
46. Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. SY Hong, MH Lee, KS Kim, HC Chung, JK Roh, WJ Hyung, SH Noh, SH Choi. World J Gastroenterol 10:1191-1197, 2004
47. Spearman’s footrule as a measure of cDNA microarray reproducibility. BS Kim, SY Rha, GB Cho, HC Chung. Genomics. 84:441-448, 2004
48. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. SJ Gong, CJ Jin, SY Rha, HC Chung. Cancer Lett 214:215-224, 2004
49. Statistical method of determining a cut off value between normal and disease group. Inyoung Kim, Yeon-ho Coi, Hyun Cheol Chung, Sun Young Rha, Byung Soo Kim. Bull Informatics and Cybernetics 36:63-72, 2004
50. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. HY Lim, MW Ahn, HC Chung, TA Gardner, CH Kao, SJ Lee, SJ Kim. Cancer Gene Ther 11:532-538, 2004
51. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS. Ann Oncol. 15:1344-1347, 2004
52. Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction. M Yeo, SY Rha, HC Jeung, XH Shen, SH Yang, SW An, JK Roh, HC Chung. FEBS Letters 579:127-132, 2005
53. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Marie Yeo, Sun Young Rha, Hei Cheul Jeung, Shen Xiong Hu, Sang Hwa Yang, Yang Seok Kim, Sung Whan An, Hyun Cheol Chung. Int J Cancer 114:484-489, 2005
54. Statistical methods of translating Microarray data into clinically relevant diagnostic information in colorectal cancer. Kim BS, Kim I, Lee S, Kim S, Rha SY, Chung HC. Bioinformatics. 21: 517-528, 2005
55. Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray Tae Moon Kim, Ha Jin Jeong, Min Young Seo, Sang Chul Kim, Gabee Cho, Chan Hee Park, Tae Soo Kim, Kyu Hyun Park, Hyun Cheol Chung, and Sun Young Rha. Clin Cancer Res 11: 79-86, 2005
56. Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients Sang Hwa Yang, Min Young Seo, Ha Jin Jeong, Hei-Cheul Jeung, Jihye Shin, Sang Chul Kim, Sung Hoon Noh, Hyun Cheol Chung, and Sun Young Rha, Clin Cancer Res 11: 612-620, 2005
57. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Sun Young Rha, Yong Hwa Moon, Hei Chul Jeung, Yong Tae Kim, Joo Hyuk Sohn, Woo Ick Yang, Chang Ok Suh, Gwi Eon Kim, Jae Kyung Roh, Hyun Cheol Chung. Breast Cancer Res Treat 90:215-221, 2005
58. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Hyun Jung Ji, Sun Young Rha, Hei Cheul Jeung, Sang Hwa Yang, Sung Wham An, Hyun Cheol Chung. Breast Cancer Res Treat, 93:227-236, 2005
59. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin, and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. YW Moon, SY Rha, HC Jeung, WI yang, CO Suh, HC Chung. Ann Oncol, 16:1778-1785, 2005
60. Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. Shim WY, Park KH, Jeung HC, Kim YT, Kim TS, Hyung WJ, An SH, Yang SH, Noh SH, Chung HC, Rha SY. Int J Mol Med. 16:857-863, 2005
61. Systematic analysis of cDNA microarray-based CGH. Park CH, Jeong HJ, Choi YH, Kim SC, Jeong HC, Park KH, Lee GY, Kim TS, Yang SW, Ahn SW, Kim YS, Rha SY, Chung HC. Int J Mol Med. 17:261-7, 2006
62. A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK, Chung HC. Oncology 70:63-70, 2006
63. Intermediate dose 5-fluorouracil-induced encephalopathy. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC. Jpn J Clin Oncol 36:55-59, 2006
64. Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. Rha SY, Jeung HC, Yanh WI, Kim JJ, Oh TJ, An SW, Chung HC. Oncol Rep. 15:749-55, 2006
65. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Woo Sun Kwon, Sun Young Rha,Yeon Ho Choi, Jung Ok Lee, Kyu Hyun Park, Jae Joon Jung, Tae Soo Kim, Hei-Cheul Jeung and Hyun Cheol Chung. Pharamcogenet Genomics 16:429-438, 2006
66. Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: a case report and review of the literature. Jong Chan Youn, Yumie Rhee, Soo Young Park, Won Ho Kim, Soo Jung Kim, Hyun Cheol Chung, Soon Won Hong, Sung-Kil Lim. Endo J 53:339-343, 2006
67. Activation of hypoxia-inducible factor 1a is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Jangsoon Lee, Soon Young Park, Eun Kyung Lee, Chang Gyo park, Hyun Cheol Chung, Sun Young Rha, Yong Kee Kim, Gyu-Un Bae, Bum Kyeong Kim, Jeung-Whan Han, Hoi Young Lee. Clin Cancer Res 12:6351-6358, 2006
68. A phase II trials of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. HC Jeung, SY Rha, BC Cho, NC Yoo, JK Roh, WJ Roh, HC Chung, JB Ahn. Br J Cancer 95:1637-1641, 2006
69. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer. A 15-year experience at a single institute. BC Cho, HC Jeung, HJ Choi, SY Rha, WJ Hyung, JH Cheong, SH Noh, HC Chung. J Surg Oncol 95:461-468, 2007
70. Identification of genes with correlated pattern of variations in copy change and expression in gastric cancer. Sang Hwa Yang, Hei-Cheul Jeung, Ha Jin Jeong, Yeon Ho Choi, Ji Eun Kim, Jae-Joon Jung, Sun Young Rha, Woo Ick Yang, Hyun Cheol Chung Genomics 89:451-459, 2007
71. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Jeung HC, Rha SY, Noh SH, Roh JK, Chung HC. Cancer Chemother Pharmacol. 59:313-320, 2007
72. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).Yeo W, Boyer M, Chung HC, Ong SY,Lim R, Zee B, Ma B, Lam KC, Mo FK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT.Cancer Chemother Pharmacol. 59:295-300, 2007
73. A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. NK Kim, SH Baik, BS Min, HR Pyo, YJ Choi, HG Kim, JS Seong, KC Keum, SY Rha, HC Chung, Int J Radiat Oncol Biol Phys 67:204-210, 2007
74. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Yong Wha Moon, Hei Cheul Jeung, Sun Young Rha, Yeon Ho Choi, Woo Ick Yang, Hyun Cheol Chung. Breast Cancer Res Treat 104:31-37, 2007
75. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, Kwon HJ. Biochem Biophys Res Commun. 356: 232-238, 2007
76. Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on microarray-CGH. SH Kang, CH Park, HC Jeung, KY Kim, SY Rha, HC Chung. Int J Mol Med 19:901-908, 2007
77. Multi-institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetics and Pharmacogenomic Evaluations. Hei-Cheul Jeung, Sun Young Rha, Hoon Kyo Kim, Ho Young Lim, Samyong Kim, Si Young Kim, Soo Jeong Gong, Chan Hee Park, Joong Bae Ahn, Sung Hoon Noh, Hyun Cheol Chung Oncologist 12:543-554, 2007
78. An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients Sun Young Rha, Hai Cheul Jeung, Yeon Ho Choi, Woo Ick Yang, Jin Ho Yoo, Byung Soo Kim, Jae Kyung Roh, Hyun Cheol Chung , Oncologist 12:622-630, 2007
79. Molecular basis of the differences between normal tumor tissues of gastric cancer. Yang S, Shin J, Park KH, Jeung HC, Rha SY, Noh SH, Yang WI, Chung HC. Biochem Biophys Acta-Molecular Basis of Disease 1772:1033-1040, 2007
80. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC, Rha SY. Int J Cancer 121:2005-2012, 2007
81. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean Institute Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Ann Surg Oncol 14: 2730-2737, 2007
82. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Baik SH, Kim NK, Lee CH, Lee KY, Sohn SK, Cho CH, Kim H, Pyo HR, Rha SY, Chung HC. Surg Today 37:455-459, 2007
83. Cetuximab rescues a patient with non-small cell lung cancer from rapid disease prrgression during chemotherapy. Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Pyo JY, Roh JK. Acta Oncol 46:547-549, 2007
84. Novel and simple transformation algorithm for combining microarray data sets. Ki Yeol Kim, Dong Hyuk Ki, Ha Jin Jeong, Hei Cheul Jeung, Hyun Cheol Chung, Sun Young Rha. BMC Bioinformatics 8:218, 2007
85. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. HC Jeung, SY Rha, SJ Shin, JB Ahn, SH Noh, JK Roh, HC Chung Brit J Cancer 97:458-463, 2007
86. Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. Jung JJ, Jeung HC, Lee JO, Kim TS, Chung HC, Rha SY. Oncol Rep 18:593-599, 2007
87. Bilateral breast cancer: Differential diagnosis using histological and biological parameters. Gong SJ, Rha SY, Jeung HC, Roh JK, Yang WI, Chung HC. Jpn J Clin Oncol 37:482-492, 2007
88. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. Gui Youn Lee, Woo Ick Yang, Hei Cheul Jeung, Sang Chul Kim, Min Young Seo, Chan Hee Park, Hyun Cheol Chung, Sun Young Rha. BMC Genomics 8:305, 2007
89. Ixabepilone plus capecutabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Eva S Thomas, Henry L Gomez, Rubi K Li, Hyun Cheol Chung, Luis E Fein, Valorie F Chan, Jacek Jassem, Xavier B Pivot, Judith V Klimovsky, Fernando Hurtado Mendoza, Binghe Xu, Mario Campone, Guillermo L lerzo, Ronald A Peck, Pralay Mukhopadhyay, Linda T Vahdat, Henri H Roche. J Clin Oncol 25:5210-5217, 2007
90. Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-linear RNA. Shin JH, Park CH, Yang YJ, Kim SC, Seo MY, Yang SH, Cho SB, Chung HC, Rha SY. Int J Mol Med 20:905-912, 2007
91. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BC Cho, JB Ahn, JS Seong, JK Roh, HC Chung, JH Sohn, NK Kim. BMC Cancer 8:8, 2008
92. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK Cancer Chemother Pharmacol. 61:75-81, 2008
93. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC. Cancer Chemother Pharmacol. 1;157-165, 2008
94. Multicenter phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J. Breast Cancer Res Treat 108: 241-250: 2008
95. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low dose leucovorin for advanced gastric cancer. Chong Kun Lim, Hei Cheul jeung, Sun Yooung Rha, Nae Choon Yoo, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Cancer Chemother Pharmacol 61:315-321, 2008
96. Novel biomarker candidates for gastric cancer. Sanghwa Yang, Hyun Cheol Chung Oncology Rep 19:675-680, 2008
97. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin and polyadenylic polyuridylic acid (poly AU) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. HC Jeung, YW Moon, SY Rha, NC Yoo, JK Roh, SH Noh, JS Min, BS Kim, HC Chung Ann Oncol 19:520-526, 2008
98. Phase II study of combination chemotherapy of 5-fluorouracil, low dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. J Jeong, HC Heung, SY Rha, CK Im, SJ Shin, JB Ahn, SH Noh, JK Roh, HC Chung. Ann Oncol 19:1135-1140, 2008
99. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastasis. SH Cheon, SY Rha, HC Jeung, CK Im, SH Kim, HR Kim, JB Ahn, JK Roh, SH Noh, HC Chung. Ann Oncol 19:1146-1153, 2008
100. Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. Ki Yeol Kim, Dong Hyuk Ki, Hei Cheul jeung, Hyun Cheol Chung, Sun Young Rha BMC Bioinformatics 9:283, 2008
101. Pemetrexed and cisplatin in patients with advanced gastric cancer: A Korean Cancer Study Group (KCSG) multicenter phase II study. Kim Yeul, Chung Hyun Cheol, Kang Won Ki, Park Sook Ryun, Kim Chul Soo, Kim Tae Yue, Shin Sang Won, Park Byung Joo, Cha Soo Jin, Bang Yung Jue. Cancer Chemother Pharmacol 62:263-270, 2008
102. Standardization of the Korea version of Mini-Mental Adjustment to cancer (K-Mini-MAC) scale: factor structure, reliability and validity. Kang JI, Chung HC, Kim SJ, Choi HJ, Ahn JB, Jeung HC, Namkoong K. Psychooncology 17:592-597, 2008
103. Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung. Cancer Lett 270:269-276, 2008
104. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Choi HJ, Kim NK, Keun KC, Cheon SH, Shin SJ, Baik SH, Cheon JH, Rha SY, Roh JK, Jeung HC, Chung HC, Ahn JB. Radiother Oncol 87:361-366, 2008
105. Variation of the 3’ telomeric overhang lengths in human cells. Lee ME, Rha SY, Jeung HC, Kim TS, Chung HC, Oh BK. Cancer Lett 264:107-118, 2008
106. Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma. Yu EJ, Lee Y, Rha SY, Kim TS, Chung HC, Oh BK, Yang WI, Noh SH, Jeung HC. Mol Cancer Res 6:1554-1566, 2008
107. Cyclo-oxygenase-2 expression in pretreatment biopsy as a predictor of tumor response after preoperative chemoradiation in rectal cancer Min BS, Choi YJ, Pyo HR, Kim H, Seong J, Chung HC, Rha SY, Kim NK Arch Surg 143:1091-1097, 2008
108. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Cancer Res 68:4277, 4286, 2008
109. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, Noh SH, Rha SY. Genomics 93:52-61, 2009
110. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Sang Gyu Lee, Young Geon Jee, Hyun Cheol Chung, Sung Bae Kim, Jungsil Ro, Young Hyuck Im, Seock Ah Im, Jae Hong Seo. Breast Cancer Res Treat 114:589-595, 2009
111. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assesment of medical literature of randomized controlled trials. Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, Noh SH, Chung HC. Cancer Chemother Pharmacol 63:912-927, 2009
112. Association of the ABCB1 gene polymorphism 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Hyun Chang, Sun Young Rha, Hei Cheul Jeung, Chong Kun Im, Joong Bae Ahn, Woo Sun Kwon, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung Ann Oncol 20:272-277, 2009
113. A multi-center phase II study of S-1 plus paclitaxel as first ?line therapy for patients with advanced or recurrent unresectable gastric cancer. Jae Jin Lee, Si-Young Kim, Hyun Cheol Chung, Kyung hee Lee, Hong Suk Song, Won Ki Kang, Young Seon Hong, In Sil Choi, Young Yeul Lee, In Sook Woo, Jin Hyuk Choi. Cancer Chemother Pharamcol 63:1083-1090, 2009
114. Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. Oh SJ, Hyung WJ, Li C, Song J, Rha SY, Chung HC, Choi SH, Noh SH. J Gastroenterol Hepatol 24:475-479, 2009
115. Copy number changes can be a predictor for hemoglobin-reduction after S-1 monotherapy in gastric cancer. . Hei Cheul Jeung, Sun Young Rha, Chan Hee Park, Chong-Kun Im, Sang Joon Shin, Joong Bae Ahn, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Int J Oncol 34:787-796, 2009
116. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Woo Sun Kwon, Sun Young Rha, Hei Cheul Jeung, Joong bae Ahn, Jae Joon Jung, Sung Hoon Noh, Hyun Cheol Chung. Cancer Lett 277:155-163, 2009
117. Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. Sun Young Rha, Hei Cheul Jeung, Min Young Seo, Sang Cheol Kim, Woo Ick Yang, Yong Wha Moon, Hyun Cheol Chung. Int J Oncol 34:837-846, 2009
118. Expression of anaphase-promoting complex 7 in fibroadenomas and phylloides tumors of breast. Yup Kang, Jang Hee Kim, Tae Hui Lee, Tai Seung Kim, Woo Hee Jung, Hyun Cheol Chung, Byeong Woo Park, Seung Soo Sheen, Jae Ho Han. Hum Pathol 40: 98-107, 2009
119. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, Chung HC, Choi SH, Noh SH. J Surg Oncol 99:275-280, 2009
120. Subtelomeric DNA methylation and telomere length in human cancer cells. Myung Eun Lee, Sun Young Rha, Hei Cheul Jeung, Hyun Cheol Chung, Bong Kyeong Oh. Cancer Letters 281:82-91, 2009
121. Prediction of recurrence of early gastric cancer after curative resection. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Rha SY, Chung HC, Choi SH, Wang LB, Noh SH. Ann Surg Oncol 16:1896-1902, 2009
122. Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer. Kim M, Chung HC. J Cancer Res Clin Oncol 135:1501-1512, 2009
123. Increment of a-dystroglycan expression in liver metastasis correlates with poor survival in gastric cancer. Yong Wha Moon, Sun Yougn Rha, Xianglan Zhang, Hei-Cheul Jeung, Woo Ick Yang, Obin Kwon, Jae Heon Jeong, Sung Hah Cheon, Nae Choon Yoo, Hyun Cheol Chung. J Surg Oncol 100:459-465, 2009
124. Changes of telomerase activity by alternative splicing of full-length and β variants of hTERT in breast cancer patients. Sun Young Rha, Hei Cheul Jeung, Kyu Hyun Park, Jin Ju Kim, and Hyun Cheol Chung. Oncol Res 18:213-220, 2009
125. A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. Chong Kun Im, Sun Young Rha, Hei Cheil Jeung, Jaeheon Jeong, Soo Hyeon Lee, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Oncology 77:349-357, 2009
126. A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. Ki Yeol Kim, Hyun Cheol Chung, Sun Young Rha. J Biosci Bioeng 108:252-258, 2009
127. Identification of significant regional genetic variations using continuous CNV values in aCGH data. Gui Youn Lee, Jin Kim, Hei-Cheul Jeung, Hyun Cheol Chung, Sun Young Rha, Ki-Yeol Kim. Genomics 94:317-323, 2009
128. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. CH Ooi, T Ivanova, J Wu, M Lee, IB Tan, J Tao, L ward, JH Koo, V Gopalakrishnan, Y Zhu, LL Cheng, J Lee, SY Rha, HC Chung, K Ganesan, J So, KH Soo, D Lim, WH Chan, WK Wong, D Bowtell, KG Yeoh, H Grabsch, A Boussioutas, P Tan. PloS Genetics 5 e1000676, 2009
129. Activity of ixabepilone in oestrogen receptor-negative and ostrogen receptor-progesterone receptor-hyman epidermal growth factor receptor 2-negative metastatic breast cancer. Pivot XB, Li RK, Thomas ES, Chung HC, Fein LE, Chan VF, Jassem J, de Mondoza FH, Mukhopadyay P, Roche HH. Eur J Cancer 45:2940-2946, 2010
130. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Kyung Soo Park, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung Invest New Drugs 28:650-658, 2010
131. Circulating Endothelial Progenitor Cells (EPC) for Tumor Vasculogenesis in Gastric Cancer Patients. Joong Bae Ahn, Sun Young Rha, Sang Joon Shin, Hei-Cheul jeung, Tae Soo Kim, Xianglan Zhang, Kyu Hyun Park, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Cancer Letters 288:124-132, 2010
132. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. Chong Kun Im, Sun Young Rha, Hei Cheul jeung, Joong Bae Ahn, Sang Joon Shin, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung, Am J Clin Oncol 33;56-60, 2010
133. Two doses of oral fluoropyrimidines S-1 of 35mg/m2 and 40mg/m2 bid: comparison of pharmacokinetic profiles in Korean patients with advanced gastric cancer. Hei Cheul Jeung, Sun Young Rha, Sang Joon Shin, Joong Bae Ahn, Sugng Hoon Noh, Jae Kyung Rog, Hyun Cheol Chung. Jpn J Clin Oncol 40:29-35, 2010
134. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. Minkyu Jung, Hei Cheul Jeung, Sung Sook Lee, Jun Yong Park, Soojung hong, Soo Hyeon Lee, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha. J Cancer Res Clin Oncol 136:517-526,2010
135. Outcomes of multiple slavage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design, YH Moon, SY Rha, HC Jeung, C Kim, MH Hong, H Chang, JK Roh, SH Noh, BS Kim, HC Chung, Cancer Chemother Pharmacol 66:797-805, 2010
136. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Hyun Chang, Sun Young Rha, Hei Cheul Jeung, Chong Kun Im, Sung Hoon Noh, Jin Ju Kim, Hyun Cheol Chung Oncology Reports 23: 271-278, 2010
137. A comparative study of protein expressions in primary colorectal cancer and synchronous hepatic metastases: The significance of MMP-1 expression as a predictor of liver metastasis. Kim, Ko, Kim, Chung, Min, Lee, Park, Kim. Scandinavian J Gastroenterol 45:217-225, 2010
138. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Hye Ryun Kim, Seong Ha Cheon, Kwang Hun Lee, Jung Ryun Ahn, Hei Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha. Int J Hyperthermia 26:305-315, 2010
139. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. Hyun Chang, Sun Young Rha, Hei-Cheul Jeung, Jae Jun Jung, Tae Soo Kim, Ho Jeong Kwon, Byung Soo Kim, Hyun Cheol Chung J Cancer Res Clin Oncol 136;1901-1913, 2010
140. Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. Chan Hee Park, Sun Young Rha, Hei Cheul Jeung, Seung Hui Kang, Dong Hyuk Ki, Won Suk Lee, Sung Hoon Noh, Hyun Cheol Chung. J Surg Oncol 102:454-461, 2010
141. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roche HH. Breast Cancer res Treat 122:409-418, 2010
142. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Jeung HC, Rha SY, Roh JK, Chung HC, Ahn JB. Radiother Oncol 95:303-307, 2010
143. Paclitaxel combined with ifosfamide in anthracycline and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. YW Moon, JH Sohn, HJ Choi, H Chang, BW Park, SI Kim, SH Park, JS Koo, YT Kim, JK Roh, HC Chung, JH Kim. Cancer Chemnother Pharmacol 66:425-431, 2010
144. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myand SP, Mullaney BP, Shen LJ, Linn C. Anti-Cancer Drugs 21:777-784, 2010.
145. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with longterm follow-up. Jung M, Shun HJ, Rha SY, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. Ann Surg Oncol 17:3259-3268, 2010.
146. Is pyridozine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine? HC Jeung and HC Chung. Asia Pac J Clin Oncol 6:141-143: 2010.
147. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Jung JJ, Noh S, Jeung HC, Jung M, Kim TS, Noh SH, Eoh JK, Chung HC, Rha SY. Cancer Sci 101:2200-2206, 2010.
148. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase III open-label, randomized controlled trial. Bang YJ, Van Custem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, ToGA trial investigators. Lancet 376;687-697, 2010.
149. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Invest New Drugs 29:1449-1458, 2011
150. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Chnag H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC. Breast Cancer Res Treat 125:55-63, 2011
151. A randomized phase II study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC. Cancer 117:2050-2057, 2011
152. Prevalence and associated factors of psychological distress among Korean cancer patients. Kim SJ, Rha SY, Song SK, Namkoong K, Chung HC, Yoon SH, Kim GM, Kim KR. Gen Hosp Psychiatry 33:246-252, 2011
153. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) is previously treated patients with adfvanced gastric cancer. Hong Jae Chon, Sun Young Rha, Hyung Soon Park, Sang Joon Shin, Hyo Song Kim, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung, Hei Cheul Jeung. Cancer Chemother Pharmacol 68:991-999, 2011
154. Predictive value of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Jeung HC, Rha SY, Shin SJ, Lim SJ, Roh JK, Noh SH, Chung HC. Anticancer Drugs 22:801-810, 2011
155. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, Chung HC, Park BW. J Cancer Res Clin Oncol 137:1123-1130, 2011
156. A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Park HS, Rha SY, Kim HS, Hyung WJ, Park JS, Chung HC, Noh SH, Jeung HC. Oncology 80:142-150, 2011
157. Biweekly gemcitabine-paclitaxel, gencitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Binghe Xu, Zefei Jiang, SB Kim, Shiying Yu-Jifeng Feng, Artur Malzyner, Auro del Giglio, HC Chung, Li Jun Shen, Daniel Lee Kay Pen. Breast Cancer 18:203-212, 2011
158. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. HS Kim, MH Hong, KE Kim, SJ Shin, JN Ahn, HC Jeung, HC Chung, YG Koh, SH Lee, YJ Bang, SY Rha. Oncology 80:395-405, 2011
159. DNA methylation predicts recurrence from resected stage III proximal colon cancer. JB Ahn, WB Chung, Osamu Maeda, SJ Shin, HS Kim, HC Chung, NK Kim, Jean-Pierre Issa. Cancer 117:1847-1854, 2011.
160. CD44-SLC1A2 gene fusions in gastric cancer. J Tao, NT Deng, K Ramnarayanan, B Huang, HK Oh, SH Leong, SS Lim, IB Tan, CH Ooi, J Wu, M Lee, S Zhang, SY Rha, HC Chung, DT Smoot, H Ashktorab, OL Kon, V Cacheux, C Yap, N Palanisamy, P Tan. Sci Transl Med 3:1-11, 2011.
161. Treatment of recurrent heparocellular carcinoma after liver transplantation. Kim HR, Cheon SH, Rha SY, Lee S, Han HK, Chon SY, Lee JD, Sung JS, Chng HC. Asia Pac J Clin Oncol 7:258-269, 2011
162. Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, Rha SY. Oncol Rep 25:717-727, 2011
163. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, Rha SY. Hepatogastroenterology. 58:2015-2019, 2011
164. Advanced detection of recent changing trends in gastric cancer survival: Up-to-date comparison by period analysis. Kim HS, Lee H, Jeung HC, Noh SH, Chung HC, Roh JK, Nam CM, Rha SY. Jpn J Clin Oncol 41:1344-1350, 2011
165. Methylation status of lamin A/C in gastric cancer cell lines. Lee WS, Jung JJ, Jeung HC, Noh SW, Oh BK, Kim KY, Kim TS, Chung HC, Roh JK, Rha SY. Hepatogastroenterology 59:115-116, 2011
166. A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures Ooi CH, Oh HK, Wang HZ, Tan AL, Wu J, Lee M, Rha SY, Chung HC, Virshup DM, Tan P. PLoS Genet e1002415, 2011
167. Adjuvant capecutabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH; CLASSIC trial investigators. Lancet 379:315-321, 2012
168. A randomized phase II trial of S1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC. Eur J Cancer 48:518-526, 2012.
169. A pilot study of S1 plus cisplatin versus 5-fluorouracil plus cisplatin for post-operative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Lee SS, Jeung HC, Chung HC, Noh SH, Hyung WJ, Ahn JY, Rha SY. Invest New Drugs 30:357-363, 2012
170. A phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. SJ Shin, JB Ahn, KS park, YJ Lee, YS Hong, TW Kim, HR Kim, SY Rha, JK Roh, DH Kim, C Kim, HC Chung. Invest New Drug 30:672-680, 2012
171. Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Kim KR, Chung HC, Lee E, Kim SJ, Namkoong K. Support Care Cancer 20:2177-2182, 2012
172. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. SW Lee, TJ Oh, HC Chung, SY Rha, CG Kim, YH Moon, BD Hoehn, DJ Jeong, SH lee, NK Kim, CH Park, MA Yoo, SW An. Int J Oncol, 40:889-898, 2012
173. FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. JI Kang, HC Chung, HC Jeung, SJ Kim, SK An, K Namkoong. Psychoneuroendocrinol 37: 1569-1576, 2012
174. Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phosphor-specific flow cytometry. Lim SM, Hwang JW, Bae SK, Bae SH, Ahn JB, Rha SY, Roh JK, Chung HC, Shin SJ. Anal Quant Cytol Histol 34:309-316, 2012
175. A phase I pharmacokinetic study of TSU-68 ( a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. Invest New Drugs 30:1501-1510, 2012
176. AMPKα Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer. Yon Hui Kim, Han Liang, Xiuping Liu, Ju-Seog Lee, Jae Yong Cho, Jae-Ho Cheong, Hoguen Kim,Min Li, Thomas J. Downey, Matthew D. Dyer, Yongming Sun, Jingtao Sun, Ellen M. Beasley, Hyun Cheol Chung, Sung Hoon Noh, John N. Weinstein, Chang-Gong Liu, Garth Powis. Cancer Res. 72:2512-21, 2012.
177. High level of serum VEGF and TIMP-2 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. Byung Soh Kim, Nam Kyu Kim, Hee Cheul Jeong, Hyun Cheol Chung. Oncol Lett 4: 123-130, 2012
178. Identification of radiosensitvity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. HS Kim, SC Kim, SJ Kim, CH Park, HC Jeung, YB Kim, JB Ahn, HC Chung, SY Rha. BMC Genomics 13;348, 2012
179. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter cross-sectional study. Oh DY, Crawford B, Kim SB, Chung HC, McDonald J, Lee SY, Ko SK, Ro J. Asia Pac J Clin Oncol 8:232-291, 2012
180. Overexpression of class III beta tubullin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. PLoS One 7:e4517, 2012
181. Epigenetic therapyusing belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the Cancer Therapeutics Research Group. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. J Clin Oncol 30:3361-3367, 2012
182. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riaha S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yang WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. Gut 61:673-684, 2012
183. Application of the Western-based adjuvant online model to Korean colon cancer patients: a single institution experience. Jung M, Kim GW, Jung I, Ahn JB, Roh JK, Rha SY, Chung HC, Kim NK, Kim TI, Shin SJ. BMC Cancer 12:471, 2012
184. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with anti-angiogenic agent. Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Invest New Drug 31:1-13, 2013
185. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. Kim YB, Jeung HC, Jeong I, Lee K, Rha SY, Chung HC, Kim GE. J Radiat Res 54:52-60, 2013
186. Changing treatment patterns in elderly patients with resectable colon cancer. Kim GM, Ahn JB, Rha SY, Kim HS, Kang B, Kim MW, Choi SY, Roh JK, Chung HC, Kim NK, Shin SJ. Asia Pac J Clin Oncol 9:265-272, 2013
187. Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Kim HS, Shin SJ, Kim SC, An S, Rha SY, Ahn JB, Cho BC, Choi HJ, Sohn JH, Kim HS, Chung HC, Kim JH, Roh JK, Lee S. Support Care Cancer 21:1751-1759, 2013
188. Randomized dose finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell CJ, Rhee BG, Patt R, Hwang TH, Kirn DH. Nat Med 19: 329-336, 2013
189. Telomerase- and angiogenesis-related gene response to irradiation in human umbilical vein endothelial cells. Hyun Chang, Sun Young Rha, Hei-Cheul Jeung, Kyu Hyun Park, Tae Soo Kim, Yong bae Kim, Hyun Cheol Chung Int J Mol Med 31:1202-1208, 2013.
190. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin-A treatment. Jung AR, Yoo JE, Shim YH, Choi NH, Jeung HC, Chung HC, Rha SY, Oh BK. Anticancer Res 33:821-829, 2013
191. Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Minkyu Jung, Eun Hee Choi, Chung Mo Nam, Sun Young Rha, Hei Cheul Jeung, Soo Hyun Lee, Woo Ick Yang, Jae Kyung, Roh & Hyun Cheol Chung. Ann Surg Oncol 20:2615-2624, 2013
192. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an onservational study. Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, Roh JK, Shin SJ. J Surg Oncol 107:613-618, 2013
193. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized, open-label phase 3 trial. Lord F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M: Arbeitsgemeinschaft Internisttische Onkologie (AIO) and EXPAND Investigators. Lancet Oncol 14:490-499, 2013
194. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. TJ Oh, NY Kim, YH Moon, MS Kim, BD Hoehn, CH Park, TS Kim, NK Kim, HC Chung, SW An. J Mol Diag 15:1-10, 2013
195. Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells. Lim SM, Hwang JW, Ahn JB, Bae SK, Park CH, Kim KY, Rha SY, Chung HC, Roh JK, Shin SJ. Anticancer Res 33:2499-2508, 2013.
196. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Lee YK, Jun HJ, Nahm JH, Lim TS, Park JS, Ahn JB, Rha SY, Chung HC, Oh HE, Song JS, Yang WI, Kim HS. Jpn J Clin Oncol 43: 996-1003, 2013.
197. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. BMC Cancer 13;394, 2013.
198. Everolimus for previously treated advanced gastric cancer; results of the randomized double-blind phase III GRANITE-1 study. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Custem E. J Clin Oncol 31:3935-3943, 2013.
199. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, Hur H, Min BS, Kim NK, Chung HC, Roh JK, Ahn JB. Ann Surg Oncol 20:3407-3413, 2013.
200. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. Ann-Lii Cheng, Yoon-Koo Kang, Deng-Yn Lin, Joong-Won Park, Masatoshi Kudo, Shukui Qin, Hyun-Cheol Chung, Xiangqun Song, Jianming Xu, Guido Poggi, Masao Omata, Susan Pitman Lowenthal, Silvana Lanzalone, Liqiang Yang, Maria Jose Lechuga and Eric Raymond. J Clin Oncol 31:4067-4075, 2013
201. S-1 combined with docetaxel following doxorubicin plus cyclophoisphamide as neoadjuvant therapy in breast cancer: phase II trial. Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J. BMC Cancer 13:583, 2013
202. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Koizumi W, Kim YH, Fuji M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inoguchi M, Tanabe K, Okuno T, Ogura M, Ypshida K, Takeuchi M, Nakajima T; The JACCRO and KCSG Study Group. J Cancer Res Clin Oncol 140: 319-328, 2014
203. Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. Lee SH, Bang YJ, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman Lowenthal S, Chung HC. Asia Pac J Clin Oncol. 10:237-245, 2014
204. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. Invest New Drugs. 32;561-568, 2014
205. Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. Zhang X, Zheng Z, Shin YK, Kim KY, Rha SY, Noh SH, Chung HC, Jeung HC. Pathology 46:316-24, 2014.
206. Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. Kim SB, Yoo C, Ro J, Im SA, Im YH, Kim JH, Ahn JH, Jung KH, Song HS, Kang SY, Park HS, Chung HC. Invest New Drugs 32: 753-776, 2014
207. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER-2 amplified advanced gastric cancer in Asian populations: Tytan-a randomizedm phase III study. Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang, Hiroto Miwa, Shu-Kui Qin, Ik Joo Chung, Kun-Huei Yeh, Ji-Feng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung-Jue Bang. J Clin Oncol 32:2039-2049, 2014
208. Quallity of life in the trastuzumab for gastric cancer trial. Taroh Saito, Yung-Jue Bang, Evgeny A. Gotovkin, Yasuo Hamamoto, Yoo-Koo Kang, Vladimir M. Moiseyenko, Atsushi Ohtsu, Eric Van Custem, Nedal Al-Sakaff, Alexa Urspruch, Julie Hill, Harald A. Webner, Hyun Cheol Chung. The Oncologist 19:1-8, 2014
209. Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. Koh MJ, Jeung HC, Namkoong K, Chung HC, Kang JI. J Psychosom Res 77:76-80, 2014
210. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. JS Park, HC Jeung, SY Rha, JB Ahn, BD Kang, HJ Chon, MH Hong, ST Lim, WI yang, CM Nam, HC Chung. Cancer Chemother Pharmacol 74:799-808, 2014
211. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. Ha Young Lee, Joong Bae Ahn, Sun Young Rha, Hyun Cheol Chung, Kyu Hyun Park, Tae Soo Kim, Nam Kyu Kim, Sang Joon Shin. World J Surg Oncol 12: 232-238, 2014
212. The effect of dysintegrin-metalloproteinase ADAM9 in gastric cancer progression. Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G. Mol Cancer Ther 13:3074-3085, 2014
213. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, JI J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial invesstigators. Lancet Oncol 15:1389-1396, 2014.
214. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. HS Park, MK Jung, HS Kim, HI Kim, JY An, JH Cheong, WJ Hyung, SH Noh, YI Kim, HC Chung, SY Rha. Ann Surg Oncol 22:224-231, 2015
215. PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. Xianglan Zhang, Ji Soo Park, Kyu Hyun Park, Ki Hyang Kim, Minkyu Jung, Hyun Cheol Chung, Sun Young Rha, Hyu Song Kim. Oncology 88:76-85, 2015
216. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Park CH, Rha SY, Ahn JB, Shin SJ, Kwon WS, Kim TS, An S, Kim NK, Yang WI, Chung HC. Int J Cancer 136:2273-2283, 2015
217. Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. Oncology 88:147-156, 2015
218. LAMC2 enhances the metastatic potential of lung adenocarcinoma. YW Moon, G Rao, JJ Kim, HS Shim, KS Park, SSAn, B Kim, PS Steeg, S Sarfaraz, L Changwoo Lee, Donna Voeller, EY Choi, Li Luo, D Palmieri, HC Chung, JH Kim, Y Wang, G Giaccone. Cell Death Diff 1:1-12, 2015
219. Dovitinib (TK1258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. CK Lee, ME Lee, WS Lee, KM Kim, KH Park, TS Kim, KY Lee, JB Ahn, HC Chung, SY Rha. Am J Cancer Res 5:72-86, 2015
220. Ramurcirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomized double-blind, multicenter, phase 3 trial. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M: REACH trial Lancet Oncol 16:859-70, 2015
221. Signatures of tumorimmunity distinguish Asian and non-Asian gastric adenocarcinomas. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Yistra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Gut 64:1721-1731, 2015
222. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. CK Lee, MK Jung, IK Jung, SJ Heo, YH Jeong, JY An, HI Kim, JH Cheong, WJ Hyung, SH Noh, HS Kim, SY Rha, HC Chung. Ann Surg 263:96-102, 2016
223. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Hong Jae Chon, Hye Ryun Kim, Eunah Shin, Chan Kim, Su Jin Heo, Choong-kun Lee, Jin Kyu Park, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha. Ann Surg Oncol 22:3938-3945, 2015
224. Do recent advances in diagnostic and therapeutic procedures negate the benefit of postmastectomy radiotherapy in N1 patients with a low risk of locoregional recurrences? Chang JS, Lee J, Kim KH, Sohn JH, Kim SI, Park BW, Chung HC, Keum KC, Suh CO, Kim YB. Medicine 94:e1259, 2015
225. Lapatinib in combination with capecitabine plus oxaliplatin inn human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma.: TRIO-013/LOGiC ? a randomized phase III trial. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk K, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houe V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. JCO 10:443-451, 2016
226. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, Mao M, Chung HC, Zheng G. Exp Mpl Pathol 100:287-293, 2016
227. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY. Oncotarget. 16;7:8055-8066, 2016.
228. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. Ann Nucl Med. 30:279-286, 2016.
229. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC. Oncotarget 7:10547-10556, 2016.
230. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Lancet Oncol. 17:717-26, 2016.
231. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, Noh SH, Jeung HC. Ann Surg 265:946-953, 2017
232. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. Min Thura, Abdul Qader Omer Al-Aidaroos, Wei Peng Yong, Koji Kono, Abhishek Gupta, You Bin Lin, Kousaku Mimura, Jean Paul Thiery, Boon Cher Goh, Patrick Tan, Ross Soo, Cheng William Hong, Lingzhi Wang, Suling Joyce Lin, Elya Chen, Sun Young Rha, Hyun Cheol Chung, Jie Li, Sayantani Nandi, Hiu Fung Yuen, Shu-Dong Zhang, Yeoh Khay Guan, Jimmy So, and Qi Zeng JCI Insight 1:e87607, 2016
233. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H.Oncotarget. 7:44608-44620, 2016
234. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. BMC Cancer. 8;16:434, 2016.
235. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, Lee KY, Kim NK, Chung HC.J Cancer Res Clin Oncol. 142:2051-2059, 2016
236. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Chow LQ, Haddad R, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee S-H, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin C-C, Chung HC, Meister A, Dolled-Fillhart M, Pathiraja K, Cheng JD, Seiwert T. J Clin Oncol. 34:3838-3845, 2016.
237. A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH. Cold Spring Harb Mol Case Stud. 2(5):a000992. doi: 10.1101/mcs.a000992, 2016
238. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I. JAMA Oncol. 2016 (in press)
239. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ. Mol Cancer Ther.16:228-238, 2017..
240. ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Ki DH, Kim TS, Chung HC. Biochem Pharmacol.123:73-84, 2017.
241. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Park HS, Sohn J, Kim SI, Park S, Park HS, Gho SG, Chung HC, Paik S, Kim GM. Breast Cancer Res Treat 163:255-262, 2017
242. Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. Sohn BS, Kim SB, Ahn JH, Jung KH, Kim J, Lee KS, Ro J, Im SA, Im YH, Song HS, Park HS, Chung HC. Asia Pac J Clin Oncol. 13:365-371, 2017
243. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. HS Kim, HN Lee, SJ Shin, SH Beom, MK Jung, SJ Bae, EY Lee, KH Park, YY Choi, TE Son, HI Kim, JH Cheong, WJ Hyung, JH Park, SK Shin, SK Lee, YC Lee, WS Koom, JS Lim, HC Chung, SH Noh, SY Rha, HK Kim, SM Park. Oncotarget 8:38389-38398, 2017
244. Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. HC Jeung, SY Rha, SJ Shin, JB Ahn, KH Park, TA Kim, JJ Kim, JK Roh, HC Chung. Oncology Letters, 14:2385-2392, 2017
245. A Phase 1, Open Label, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MG1102 (Apolipoprotein(a) Kringle V) in Patients with Solid Tumors. Gun Min Kim, Tony Reid, Sang Joon Shin, Sun Young Rha, Joong Bae Ahn, Sung Sil Lee, Hyun Cheol Chung. Invest New Drugs, 35: 773-781, 2017
246. Trastuzumab emtansine versus taxane use for previously treated HER-2 positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomized open-label adaptive phase 2/3 study. Thuss-Patience PC, Shah MA, Ohtsu A, Custem EV, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, Horst T, Harle-Yge ML, Althaus BL, Kang YK. Lancet Oncology 18:640-653, 2017
247. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M. Oncotarget 8:31169-31179, 2017
248. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, Chung HC, Kim KR, Rha SY. BMC Cancer. 2017 17:283. doi: 10.1186/s12885-017-3260-2
249. Modulation of HAT activity by the BRCA2N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Kwon WS, Rha SY, Jeung HC, Kim TS, Chung HC. Biochem Pharmacol. 138: 163-173, 2017
250. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M .Gastric Cancer. 2017 Jun 22. doi: 10.1007/s10120-017-0739-0. [Epub ahead of print]
251. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Eur J Cancer 81:17-25, 2017
252. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT. Clin Cancer Res. 23:5981-5992, 2017.
253. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T. Cancer Chemother Pharmacol. 80:1197-1207, 2017
254. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Lancet. 390: 2461-2471, 2017
255. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, Rha SY, Chung HC, Kang SM, Jung M. Oncotarget. 8: 61837-61845, 2017.
256. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Chan Kim, Choong-kun Lee, Hong Jae Chon1, Joo Hoon Kim, Hyung Soon Park, Su Jin Heo, Hyun Jeong Kim, Tae Soo Kim, Woo Sun Kwon, Hyun Cheol Chung and Sun Young Rha. Oncotarget 8:113494-113501, 2017.
257. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: analyses from KEYNOTE-012. Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Bhumsuk Keam, Takahashi K, Cheng JD, Bang YJ. Cancer Sci. 2017 Dec 28. doi: 10.1111/cas.13480. [Epub ahead of print]
258. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S. Clin Epigenetics. 2017 Dec 4;9:126. doi: 10.1186/s13148-017-0426-3. eCollection 2017.
259. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY. Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31304. [Epub ahead of print]
260. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS. BMC Cancer 18(1):158, 2018. doi: 10.1186/s12885-018-4066-6.
261. Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. Chung HC, Kok VC, Cheng R, Hsu Y, Orlando M, Fuchs C, Cho JY. Asia Pac J Clin Oncol. 2018 Jan 10. doi: 10.1111/ajco.12829. [Epub ahead of print]
263. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T.Cancer Chemother Pharmacol. 80:1197-1207, 2017
264. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, Chia-Chi Lin, Bhumsuk Keam, Kenichi Takahashi, Jonathan D. Cheng, Yung-Jue Bang. Cancer Sci 109: 771?776, 2018
Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer
ONCOLOGIST 24/11 :e1108-e1114,2019
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
EUROPEAN JOURNAL OF CANCER 112/ :20-28,2019
Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
GASTRIC CANCER 22/6 :1,153-1,163,2019
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
Journal for ImmunoTherapy of Cancer 7/1 :e268-,2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
JAMA Network Open 2/8 :e198243-,2019
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.
CANCER RESEARCH AND TREATMENT 51/4 :1,578-1,588,2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
GASTRIC CANCER 22/4 :828-837,2019
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
CANCER RESEARCH AND TREATMENT 51/3 :851-860,2019
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
ONCOLOGY 96/2 :59-69,2019
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
CANCER RESEARCH AND TREATMENT 51/2 :819-831,2019
Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
CANCER RESEARCH AND TREATMENT 51/1 :211-222,2019
A multicenter phase II study of AMG 337 in patients with MET-amplified gastric/gastroesophageal junction/esophageal adenocarcinoma and other MET-amplified solid tumors
CLINICAL CANCER RESEARCH 25/8 :2,414-2,423,2019
Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer
RADIOTHERAPY AND ONCOLOGY 140/ :143-149,2019
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
FUTURE ONCOLOGY 15/6 :567-577,2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
JOURNAL OF CLINICAL ONCOLOGY 37/17 :1,470-1,478,2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial
Journal for ImmunoTherapy of Cancer 7/1 :30-,2019
Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 34/1 :84-91,2019
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials
CLINICAL BREAST CANCER 18/6 :489-497,2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
LANCET 392/10142 :123-133,2018
Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 22/12 :5,899-5,908,2018
Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
ANTICANCER RESEARCH 38/11 :6,171-6,180,2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
Journal of Global Oncology 4/ :1-12,2018
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
JOURNAL OF SURGICAL ONCOLOGY 117/8 :1,679-1,686,2018
Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
AAPS JOURNAL 20/4 :72-87,2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
BRITISH JOURNAL OF CANCER 119/2 :153-159,2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
BRITISH JOURNAL OF CANCER 119/1 :19-26,2018
The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
GASTRIC CANCER 21/2 :213-224,2018
Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 14/3 :204-209,2018
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor
INTERNATIONAL JOURNAL OF CANCER 143/1 :151-159,2018
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
CANCER SCIENCE 109/3 :771-776,2018
Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
BMC CANCER 18/1 :158-165,2018
PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
ONCOTARGET 8/69 :113,494-113,501,2017
Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer
CLINICAL EPIGENETICS 9/1 :126-137,2017
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 80/6 :1,197-1,207,2017
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
LANCET 390/10111 :2,461-2,471,2017
A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
INVESTIGATIONAL NEW DRUGS 35/6 :773-781,2017
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
CLINICAL CANCER RESEARCH 23/19 :5,981-5,992,2017
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13/6 :365-371,2017
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
ONCOTARGET 8/37 :61,837-61,845,2017
HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib
MOLECULAR CANCER THERAPEUTICS 16/1 :228-238,2017
Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer
ONCOLOGY LETTERS 14/2 :2,385-2,392,2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
EUROPEAN JOURNAL OF CANCER 81/ :17-25,2017
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
ONCOTARGET 8/24 :38,389-38,398,2017
Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines
BIOCHEMICAL PHARMACOLOGY 138/ :163-173,2017
Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
ONCOTARGET 8/19 :31,169-31,179,2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
LANCET ONCOLOGY 18/5 :640-653,2017
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
BREAST CANCER RESEARCH AND TREATMENT 163/2 :255-262,2017
Prevalence and prognostic implications of psychological distress in patients with gastric cancer
BMC CANCER 17/1 :283-,2017
Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
ANNALS OF SURGERY 265/5 :946-953,2017
ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition
BIOCHEMICAL PHARMACOLOGY 123/ :73-84,2017
A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE 2/5 :a000992-,2016
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
ONCOTARGET 7/9 :10,547-10,556,2016
High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 142/9 :2051-2059,2016
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
ONCOTARGET 7/28 :44608-44620,2016
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC - A randomized phase III trial
JOURNAL OF CLINICAL ONCOLOGY 34/5 :443-451,2016
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
BMC CANCER 16/434 :1-7,2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
LANCET ONCOLOGY 17/6 :717-726,2016
Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
ONCOTARGET 7/7 :8055-8066,2016
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
CANCER RESEARCH AND TREATMENT 48/2 :499-507,2016
Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples
EXPERIMENTAL AND MOLECULAR PATHOLOGY 100/2 :287-293,2016
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
ANNALS OF SURGERY 263/1 :96-102,2016
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer
ANNALS OF SURGICAL ONCOLOGY 22/12 :3938-3945,2015
The Impact of Coping Styles on Psychological Distress and Quality of Life in Korean Patients with Cancer
Korean Journal of Psycho-Oncology(정신종양학회지) 1/1 :36-42,2015
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.
GUT 64/11 :1721-1731,2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial
LANCET ONCOLOGY 16/7 :859-870,2015
LAMC2 enhances the metastatic potential of lung adenocarcinoma
CELL DEATH AND DIFFERENTIATION 22/8 :1341-1352,2015
Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
ONCOLOGY 88/3 :147-156,2015
Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
MEDICINE 94/33 :1-9,2015
Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer
AMERICAN JOURNAL OF CANCER RESEARCH 5/1 :72-86,2015
PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity
INTERNATIONAL JOURNAL OF CANCER 136/10 :2273-2283,2015
Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
ONCOLOGY 88/2 :76-85,2015
The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression.
MOLECULAR CANCER THERAPEUTICS 13/12 :3074-3085,2014
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
LANCET ONCOLOGY 15/12 :1389-1396,2014
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
WORLD JOURNAL OF SURGICAL ONCOLOGY 12/- :232-238,2014
Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 10/3 :237-245,2014
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
INVESTIGATIONAL NEW DRUGS 32/4 :753-761,2014
Quality of Life in the Trastuzumab for Gastric Cancer Trial
ONCOLOGIST 19/7 :712-719,2014
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
JOURNAL OF CLINICAL ONCOLOGY 32/19 :2039-89,2014
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
INVESTIGATIONAL NEW DRUGS 32/3 :561-568,2014
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer
PATHOLOGY 46/4 :316-324,2014
Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer
JOURNAL OF PSYCHOSOMATIC RESEARCH 77/1 :76-80,2014
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START)
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 140/2 :319-328,2014
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
JOURNAL OF CLINICAL ONCOLOGY 31/32 :4067-4075,2013
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
JOURNAL OF CLINICAL ONCOLOGY 31/31 :3935-3943,2013
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial
BMC CANCER 13/583 :1-7,2013
Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study
ANNALS OF SURGICAL ONCOLOGY 20/11 :3407-3413,2013
Changing treatment patterns in elderly patients with resectable colon cancer
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 9/3 :265-272,2013
Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells
ANTICANCER RESEARCH 33/6 :2499-2508,2013
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer
JOURNAL OF MOLECULAR DIAGNOSTICS 15/4 :498-507,2013
Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
LANCET ONCOLOGY 14/6 :490-499,2013
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
BMC CANCER 13/394 :1-7,2013
Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
ANNALS OF SURGICAL ONCOLOGY 20/8 :2615-2624,2013
Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study
JOURNAL OF SURGICAL ONCOLOGY 107/6 :613-618,2013
Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 31/5 :1202-1208,2013
Increased Alternative Lengthening of Telomere Phenotypes of Telomerase-negative Immortal Cells upon Trichostatin ？ A Treatment
ANTICANCER RESEARCH 33/3 :821-830,2013
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
NATURE MEDICINE 19/3 :329-336,2013
Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
JOURNAL OF RADIATION RESEARCH 54/1 :52-60,2013
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
INVESTIGATIONAL NEW DRUGS 31/1 :1-13,2013
Quantitative Analysis of ERK Signaling Inhibition in Colon Cancer Cell Lines Using Phospho-Specific Flow Cytometry
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 34/ :309-316,2012
Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
BMC GENOMICS 13/348 :-,2012
Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
BMC CANCER 12/1 :471-471,2012
A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeuti
JOURNAL OF CLINICAL ONCOLOGY 30/27 :3361-3367,2012
Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 8/3 :282-291,2012
Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
PLOS ONE 7/9 :e45127-e45127,2012
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
GUT 61/5 :673-684,2012
High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection.
Oncology letters 4/1 :123-130,2012
FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study
PSYCHONEUROENDOCRINOLOGY 37/ :1569-1576,2012
Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism
SUPPORTIVE CARE IN CANCER 20/ :2177-2182,2012
AMPK alpha Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer
CANCER RESEARCH 72/10 :2512-2521,2012
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
INVESTIGATIONAL NEW DRUGS 30/ :672-680,2012
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
EUROPEAN JOURNAL OF CANCER 48/ :518-526,2012
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer
INVESTIGATIONAL NEW DRUGS 30/ :357-363,2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
LANCET 379/9813 :315-321,2012
Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer
INTERNATIONAL JOURNAL OF ONCOLOGY 40/3 :889-898,2012
Methylation Status of Lamin A/C in Gastric Cancer Cell Lines
HEPATO-GASTROENTEROLOGY 59/116 :1313-1318,2012
DNA Methylation Predicts Recurrence From Resected Stage III Proximal Colon Cancer
CANCER 117/9 :1847-1854,2011
MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer
HEPATO-GASTROENTEROLOGY 58/112 :2015-2019,2011
A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures
PLOS GENETICS 7/12 :-,2011
Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41/ :1344-1350,2011
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
INVESTIGATIONAL NEW DRUGS 29/ :1449-1458,2011
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 68/0 :991-999,2011
Treatment of recurrent hepatocellular carcinoma after liver transplantation
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 7/3 :258-269,2011
Inflammatory and Tumor Stimulating Responses after Laparoscopic Sigmoidectomy
YONSEI MEDICAL JOURNAL 52/4 :635-642,2011
CD44-SLC1A2 Gene Fusions in Gastric Cancer
SCIENCE TRANSLATIONAL MEDICINE 3/77 :1-11,2011
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
BREAST CANCER 18/3 :203-212,2011
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
ONCOLOGY 80/5-6 :395-405,2011
A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
ONCOLOGY 80/1-2 :142-150,2011
Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer
ANTI-CANCER DRUGS 22/8 :801-810,2011
A Randomized Phase 2 Study of Docetaxel and S-1 Versus Docetaxel and Cisplatin in Advanced Gastric Cancer With an Evaluation of SPARC Expression for Personalized Therapy
CANCER 117/10 :2050-2057,2011
Prevalence and associated factors of psychological distress among Korean cancer patients
GENERAL HOSPITAL PSYCHIATRY 33/3 :246-252,2011
Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 137/7 :1123-1130,2011
Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis
ONCOLOGY REPORTS 25/3 :717-727,2011
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells
BREAST CANCER RESEARCH AND TREATMENT 125/1 :55-63,2011
Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
International Journal Of Hyperthermia 26/4 :305-315,2010
Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
Cancer Research and Treatment 42/4 :217-224,2010
The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
Annals of Surgical Oncology 17/12 :3259-3268,2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Lancet 376/9742 :687-697,2010
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/3 :425-431,2010
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
Asia-Pacific Journal Of Clinical Oncology 6/3 :141-143,2010
Identification of Novel Gastric Cancer-Associated CNVs by Integrated Analysis of Microarray
Journal Of Surgical Oncology 102/5 :454-461,2010
Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
CANCER SCIENCE 101/10 :2200-2206,2010
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
Investigational New Drugs 28/5 :650-658,2010
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/4 :797-805,2010
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
Breast Cancer Research and Treatment 122/2 :409-418,2010
A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: The significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis
Scandinavian Journal Of Gastroenterology 45/2 :217-225,2010
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma
Anti-Cancer Drugs 21/8 :777-784,2010
Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
Radiotherapy And Oncology 95/3 :303-307,2010
The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/ :517-526,2010
Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/12 :1901-1913,2010
A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer
American Journal of Clinical Oncology-Cancer Clinical Trials 33/1 :56-60,2010
Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy
Oncology Reports 23/ :271-278,2010
Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m(2) bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40/1 :29-35,2010
Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients
Cancer Letters 288/1 :124-132,2010
Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction
Yonsei Medical Journal 50/2 :296-299,2009
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer
European Journal Of Cancer 45/17 :2940-2946,2009
Changes of Telomerase Activity by Alternative Splicing of Full-Length and beta Variants of hTERT in Breast Cancer Patients
Oncology Research 18/5-6 :213-220,2009
Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
Cancer Research And Treatment 41/4 :196-204,2009
A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status
Oncology 77/6 :349-357,2009
Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer
Journal Of Surgical Oncology 100/6 :459-465,2009
Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 135/11 :1501-1512,2009
Prognosis of pN3 stage gastric cancer
Cancer Research And Treatment 41/2 :73-79,2009
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
Cancer Research And Treatment 41/2 :67-72,2009
oncogenic pathway combinations predict clinical prognosis in gastric cancer
Plos Genetics 5/ :e1000676-,2009
Genetic and Epigenetic Marker-Based DNA Test of Stool Is a Promising Approach for Colorectal Cancer Screening
Yonsei Medical Journal 50/3 :331-334,2009
A weighted sample size for microarray datasets that considers the variability of variance and multiplicity
Journal Of Bioscience And Bioengineering 108/3 :252-258,2009
Identification of significant regional genetic variations using continuous CNV values in aCGH data
Genomics 94/3 :317-323,2009
Prediction of recurrence of early gastric cancer after curative resection
Annals Of Surgical Oncology 16/7 :1896-1902,2009
Subtelomeric DNA methylation and telomere length in human cancer cells
Cancer Letters 281/1 :82-91,2009
Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer
International Journal Of Oncology 34/3 :787-796,2009
Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery
International Journal Of Oncology 34/ :837-846,2009
Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma
Journal Of Gastroenterology And Hepatology 24/3 :475-479,2009
The Effect of Spleen-Preserving Lymphadenectomy on Surgical Outcomes of Locally Advanced Proximal Gastric Cancer
Journal Of Surgical Oncology 99/ :275-280,2009
G-T haplotype (2677G > T/A and 3435C > T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern
Cancer Letters 277/2 :155-163,2009
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/ :1083-1090,2009
Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
Breast Cancer Research And Treatment 114/3 :589-595,2009
Prediction of S-1-induced anemia
GASTRIC CANCER 12/ :23-30,2009
Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials
CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/5 :919-927,2009
Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
Annals Of Oncology 20/2 :272-277,2009
Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast
Human Pathology 40/1 :98-107,2009
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer
Genomics 93/ :52-61,2009
Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer
Cancer Letters 270/2 :269-276,2008
Disease Prediction Using Ranks of Gene Expressions
Genomics & Informatics 6/3 :136-141,2008
Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity
Psycho-Oncology 17/ :592-597,2008
Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
Annals Of Oncology 19/6 :1135-1140,2008
Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer
Archives Of Surgery 143/ :1091-1097,2008
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma
Molecular Cancer Research 6/10 :1554-1566,2008
S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer
The Korean Journal Of Internal Medicine 23/1 :37-41,2008
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene
Cancer Research 68/ :4277-4286,2008
Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions
Bmc Bioinformatics 9/ :-,2008
Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases
Annals Of Oncology 19/ :1146-1153,2008
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A : U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
Annals Of Oncology 19/ :520-526,2008
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer
Cancer Chemotherapy And Pharmacology 61/ :315-321,2008
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
Cancer Chemotherapy And Pharmacology 62/ :263-270,2008
Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: Long-term results in 31 patients
Bmc Cancer 8/ :-,2008
Novel biomarker candidates for gastric cancer
Oncology Reports 19/ :675-680,2008
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
Cancer Chemotherapy And Pharmacology 61/ :75-81,2008
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
Cancer Chemotherapy And Pharmacology 61/ :157-165,2008
Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
Radiotherapy And Oncology 87/ :361-366,2008
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Breast Cancer Research And Treatment 108/ :241-250,2008
Variation of the 3 ` telomeric overhang lengths in human cells
Cancer Letters 264/ :107-118,2008
화학요법 치료 중인 암 환자에서의 Vibrio fluvialis 균혈증 2례
대한임상미생물학회지 10/2 :164-167,2007
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
JOURNAL OF CLINICAL ONCOLOGY 25/33 :5210-5217,2007
A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and ...
BREAST CANCER RESEARCH AND TREATMENT 39/3 :134-137,2007
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: A 15-year follow-up study at a single korean institute
ANNALS OF SURGICAL ONCOLOGY 14/ :2730-2737,2007
Novel and simple transformation algorithm for combining microarray data sets
BMC BIOINFORMATICS 8/ :310-316,2007
Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization
BMC GENOMICS 8/ :749-754,2007
An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions
Cancer Research and Treatment 39/2 :74-81,2007
Molecular basis of the differences between normal and tumor tissues of gastric cancer
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1772/ :1033-1040,2007
A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 59/ :313-320,2007
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 356/1 :233-238,2007
Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents
ONCOLOGY REPORTS 18/ :593-599,2007
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients
ONCOLOGIST 12/ :622-630,2007
Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute
JOURNAL OF SURGICAL ONCOLOGY 95/ :461-468,2007
Whole genome analysis for liver metastasis gene signatures in colorectal cancer
INTERNATIONAL JOURNAL OF CANCER 121/ :2005-2012,2007
Gastrointestinal stromal tumor of the rectum: An analysis of seven cases
SURGERY TODAY 37/6 :455-459,2007
Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
ACTA ONCOLOGICA 46/4 :547-549,2007
Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
ONCOLOGIST 12/5 :543-554,2007
A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
BRITISH JOURNAL OF CANCER 97/ :458-463,2007
A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 67/1 :204-210,2007
Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-amplified RNA
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20/6 :905-912,2007
Bilateral breast cancer: Differential diagnosis using histological and biological parameters
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 37/ :487-492,2007
Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer
BREAST CANCER RESEARCH AND TREATMENT 104/ :31-37,2007
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer
GENOMICS 89/ :451-459,2007
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
CANCER CHEMOTHERAPY AND PHARMACOLOGY 59/ :295-300,2007
Integrated in silico and biological validation of the blocking effect of C(o)t-1 DNA on microarray-CGH
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 19/ :901-908,2007
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
BRITISH JOURNAL OF CANCER 95/ :1637-1641,2006
A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer
ONCOLOGY 70/ :63-70,2006
Intermediate dose 5-fluorouracil-induced encephalopathy
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 36/ :55-59,2006
유방암의 전신적 재발로 오인된 톡소플라스마증 1예
대한내과학회지(korean Journal of medcine) 71/1 :108-113,2006
Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
PHARMACOGENETICS AND GENOMICS 16/ :429-438,2006
Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer.
ONCOLOGY REPORTS 15/ :749-755,2006
Activation of hypoxia-inducible factor-1α is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression
CLINICAL CANCER RESEARCH 12/21 :6351-6358,2006
Significant Gene Selection Using Integrated Microarray Data Set with Batch Effect
GENOMICS & INFORMATICS 4/3 :110-117,2006
Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
CANCER RESEARCH AND TREATMENT 38/3 :184-188,2006
Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: A case report and review of the literature
ENDOCRINE JOURNAL 53/3 :339-343,2006
Systematic analysis of cDNA microarray-based CGH.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 17/ :261-267,2006
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
ANNALS OF ONCOLOGY 16/ :1778-1785,2005
A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma
YONSEI MEDICAL JOURNAL 46/6 :799-805,2005
Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction
FEBS LETTERS 579/ :127-132,2005
Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 16/5 :857-863,2005
Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells
INTERNATIONAL JOURNAL OF CANCER 114/ :484-489,2005
Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients
CLINICAL CANCER RESEARCH 11/ :612-620,2005
Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray
CLINICAL CANCER RESEARCH 11/ :79-86,2005
Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss
BREAST CANCER RESEARCH AND TREATMENT 93/ :227-236,2005
직장암에서 전 직장간막 절제술 후 측방절제연이 예후에 미치는 영향
대한대장항문학회지(Journal Of The Korean Society Of Coloproctology) 21/5 :307-313,2005
진행된 직장암에서 수술 전 화학 방사선 요법 후 전직장간막절제술의 임상적 고찰: 병리학적 T 병기와 N 병기하강에 따른 임상 결과 분석
대한외과학회지 68/3 :218-223,2005
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
BREAST CANCER RESEARCH AND TREATMENT 90/3 :215-221,2005
직장에 발생한 위장관 간질종양 7예
대한외과학회지 68/2 :117-122,2005
Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus
CANCER GENE THERAPY 11/8 :532-538,2004
Coordination modes vs. antitumor activity: Synthesis and antitumor activity of novel platinum(II) complexes of N-substituted amino dicarboxylic acids
JOURNAL OF INORGANIC BIOCHEMISTRY 98/1 :98-104,2004
The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 13/1 :17-24,2004
Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines
CANCER LETTERS 214/ :215-224,2004
Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas
LEUKEMIA & LYMPHOMA 45/9 :1857-1864,2004
Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix: A Potential Predictor of Poor Survival
CLINICAL CANCER RESEARCH 10/4 :1366-1374,2004
Statistical methods of determining a cut off value between normal and disease groups
Bulletin of Informatics and Cybernetics 36/ :63-72,2004
MN/CA9 촉진자를 가진 Replication-competent 아데노바이러스를 이용한 신세포암에 대한 종양 특이적 유전자요법
Korean Journal of Urology 45/5 :456-462,2004
Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model
WORLD JOURNAL OF GASTROENTEROLOGY 10/8 :1191-1197,2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
ANNALS OF ONCOLOGY 15/ :1344-1347,2004
국소 진행된 직장암의 수술 전 화학방사선 요법 치료 후 종양반응 분석: 종양체적 변화와 병리조직학적 병기하강과의 상관관계 분석
대한대장항문학회지(Journal Of The Korean Society Of Coloproctology) 20/5 :296-302,2004
A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma
YONSEI MEDICAL JOURNAL 44/3 :539-543,2003
Infusional Fluorouracil, Etoposide, and Cisplatin(FEP) in Advanced and Relapsed Gastric Cancer
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 26/2 :203-209,2003
Region of allelic imbalance in the distal portion of chromosome 12q in gastric cancer
MOLECULAR PHARMACOLOGY 0/0 :0-0,2003
Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray
Int J Oncology 22/0 :741-750,2003
cDNA microarray experiment: disign issues in early stage and the need of normalization
CANCER RESEARCH AND TREATMENT 35/6 :533-540,2003
Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
BRITISH JOURNAL OF SURGERY 89/4 :460-466,2002
Changes of telomerase activity and proliferation by inhibition of reverse transcriptase activity in human cancer cell.
Cencer Research and Treatment 34/0 :223-233,2002
A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane
CANCER RESEARCH AND TREATMENT 34/4 :274-279,2002
Suppression of peritoneal metastasis by expression of murine endostatin cDNA
CANCER RESEARCH AND TREATMENT 34/4 :302-307,2002
Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.
Int J Mol Oncol 10/3 :251-256,2002
Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
Cancer Research and Treatment 33/6 :520-526,2001
전이성 유방암의 치료
Current diagnosis and management of cancer 1/3 :171-180,2001
암치료에 있어 혈관신생 연구
대한내분비학회지(Joornal of the Korean Society of Endocrinol) 16/3 :313-327,2001
A phase II study of genexol in metastatic breast cancer
BULLETIN OF THE KOREAN CHEMICAL SOCIETY 33/6 :451-457,2001
The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck
CANCER 91/0 :2343-2352,2001
Leptomeningeal Carcinomatosis in Solid Tumors ; Clinical Manifestation and Treatment
대한암학회지 33/1 :34-40,2001
Intravenous 5-fluorouracil versus oral doxifluridine as pre-operative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 31/0 :25-29,2001
Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
CANCER 91/11 :2016-2025,2001
5-days 5-fluorouracil and low dose leucovorin for adjuvant chemotherapy in colon cancer
CANCER LETTERS 167/0 :215-224,2001
Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
대한암학회지 33/6 :520-526,2001
Early post-operative intraperitoneal chemotherapy with mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer
ONCOLOGY 60/1 :24-30,2001
Tissue urokinase-type plasminogen activator receptor levels in breast cancer
International J Mol Medicine 6/0 :301-305,2000
국소진행성 직장암에서 수술전 방사선 및 항암화학 동시요법의 효과
대한방사선종양학회지(Journal Of The Korean Society For Therapeutic Radiology And Oncology) 18/4 :293-299,2000
정상임신과 자궁외 임신 사이의 융모막 융모 telomerase 활성도의 비교
대한산부회지 43/8 :1431-1436,2000
유방암의 출력 도플러 초음파 소견: 병리학적 미세혈관 정도 및 림프절 전이와 비교
대한초음파의학회지(Journal Of The Korean Society Of Medical Ultrasound) 19/ 4 :319-323,2000
위암에서 ex vivo Model 을 이용한 MMP - 9 에 대한 Gabexate Mesylate IC50의 응용 : 예후인자 및 치료대상 선정기준
대한암학회지 32/1 :7-18,2000
유방암 조직에서 uPAR 발현의 임상적 의의
대한암학회지 32/0 :53-59,2000
Correlation of tissue and blood plasminogen activation system in breast cancer
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 150/0 :137-145,2000